Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure-Response Analysis.

Abstract

This study evaluated the benefit/risk of trastuzumab deruxtecan (T-DXd) 6.4mg/kg in patients with human epidermal growth factor receptor2 (HER2)-positive gastric cancer using pharmacometrics. A population pharmacokinetic (PopPK) model was developed using data from patients with gastric cancer, breast cancer, or other tumors in T-DXd clinical trials, primarily conducted in Asia. Posthoc model-estimated pharmacokinetic metrics were used in exposure-efficacy (objective response rates, ORRs) and exposure-safety analyses. The PopPK analysis included 808 patients (217 with gastric cancer, 512 with breast cancer, and 79 with other cancers). In gastric cancer, the T-DXd 6.4mg/kg steady-state exposure metrics were lower compared with 6.4mg/kg in breast cancer, but were similar to 5.4mg/kg in breast cancer. Tumor type was selected as a significant covariate on T-DXd clearance. In exposure-efficacy analysis among 160 patients with gastric cancer, the T-DXd steady-state minimum concentration was associated with a confirmed ORR in univariate logistic regression analysis (P=.023). The model-predicted confirmed ORRs in gastric cancer were 36.0% (90%CI 29.3% to 43.7%) with 5.4mg/kg and 40.0% (90%CI 33.1% to 47.6%) with 6.4mg/kg. Among 808 patients in the exposure-safety analyses, the model-predicted estimates for the rates of any-grade interstitial lung disease (ILD) over a period of 180days were 10.2% (90%CI 8.7% to 12.8%) with 6.4mg/kg in gastric cancer and 9.7% (90%CI 8.2% to 11.8%) with 5.4mg/kg in breast cancer. In gastric cancer, the efficacy of T-DXd was higher at 6.4mg/kg than at 5.4mg/kg. Exposure and ILD rates were comparable between 6.4mg/kg in gastric cancer and 5.4mg/kg in breast cancer. This study identified T-DXd 6.4mg/kg as the recommended dose in HER2-positive gastric cancer.